Kyle Mikson Analyst Performance

Managing Director, Senior Research Analyst at Canaccord Genuity Group

Kyle Mikson is a stock analyst at Canaccord Genuity Group focused in the medical sector, covering 13 publicly traded companies. Over the past year, Kyle Mikson has issued 24 stock ratings, including buy and hold recommendations. While full access to Kyle Mikson's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kyle Mikson's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 40 Last 3 Years
Buy Recommendations: 74.29% 26 Buy Ratings
Companies Covered: 13 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	74.3%	26 ratings
Hold	25.7%	9 ratings
Sell	0.0%	0 ratings

Out of 35 total stock ratings issued by Kyle Mikson at Canaccord Genuity Group, the majority (74.3%) have been Buy recommendations, followed by 25.7% Hold.

Best & Worst Calls

Best Call
0000.0%
PACB
Aug 2022
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
TTOO
Feb 2022
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	13 companies

Kyle Mikson, an analyst at Canaccord Genuity Group, currently covers 13 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 12 companies	92.3%
	Computer and Technology 1 company	7.7%

Kyle Mikson of Canaccord Genuity Group specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 4 companies	30.8%
MED PRODUCTS 2 companies	15.4%
MEDICAL SERVICES 2 companies	15.4%
MED INSTRUMENTS 2 companies	15.4%
ELEC COMP - SEMIC 1 company	7.7%
MEDICAL INFO SYS 1 company	7.7%
SURGICAL & MEDICAL INSTRUMENTS 1 company	7.7%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
QSI Quantum-Si	9/9/2025	Reiterated Rating	$1.08	$1.00	Hold
CSTL Castle Biosciences	9/9/2025	Reiterated Rating	$24.05	$37.00	Buy
TXG 10x Genomics	8/11/2025	Set Price Target	$12.41	$16.00
QTRX Quanterix	8/11/2025	Reiterated Rating	$4.75	$5.00	Hold
ILMN Illumina	8/1/2025	Boost Price Target	$96.17	$105.00	Hold
XGN Exagen	7/30/2025	Boost Price Target	$8.45	$11.00	Buy
ILMN Illumina	6/11/2025	Boost Price Target	$87.98	$99.00	Hold
BDSX Biodesix	5/14/2025	Lower Price Target	$0.22	$1.50	Buy
XGN Exagen	5/13/2025	Boost Price Target	$5.48	$8.00	Buy
QTRX Quanterix	5/13/2025	Lower Price Target	$4.75	$12.00	Buy
ILMN Illumina	5/12/2025	Lower Price Target	$75.76	$87.00	Hold
TXG 10x Genomics	5/12/2025	Lower Price Target	$9.44	$15.00	Buy
CSTL Castle Biosciences	5/6/2025	Lower Price Target	$18.75	$37.00	Buy
GH Guardant Health	5/1/2025	Boost Price Target	$48.89	$65.00	Buy
ILMN Illumina	4/29/2025	Lower Price Target	$77.22	$92.00	Hold
BDSX Biodesix	4/29/2025	Lower Price Target	$0.57	$2.50	Buy
GRAL GRAIL	4/21/2025	Initiated Coverage	$27.00	$32.00	Buy
PACB Pacific Biosciences of California	4/10/2025	Reiterated Rating	$1.38	$3.00	Buy
QTRX Quanterix	3/18/2025	Lower Price Target	$7.28	$15.00	Buy
ILMN Illumina	3/11/2025	Lower Price Target	$85.97	$115.00	Hold
NTRA Natera	2/26/2025	Reiterated Rating	$161.43	$180.00	Buy
GH Guardant Health	2/24/2025	Boost Price Target	$42.87	$60.00	Buy
TXG 10x Genomics	2/13/2025	Lower Price Target	$11.94	$18.00	Buy
ILMN Illumina	2/7/2025	Lower Price Target	$112.34	$135.00	Hold

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.